Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Angi Q1 Earnings

Angi (NASDAQ:ANGI) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:10 PM. Here’s what investors…
byBenzinga Insights
May 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Angi (NASDAQ:ANGI) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:10 PM.

Here’s what investors need to know about the announcement.

Earnings

Angi beat estimated earnings by 50.0%, reporting an EPS of $-0.03 versus an estimate of $-0.06.

Revenue was down $43.75 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.02 which was followed by a 8.27% drop in the share price the next day.

Here’s a look at Angi’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.04 -0.03 -0.06 -0.06
EPS Actual -0.06 -0.03 -0.05 -0.07
Revenue Estimate 444.99M 502.91M 492.76M 433.38M
Revenue Actual 441.55M 498.04M 515.78M 436.16M

To track all earnings releases for Angi visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

By Jelena Martinovic
May 16, 11:25 AM
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB